Dirk Klingbiel
Bristol-Myers Squibb (Switzerland)(CH)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Genetic factors in colorectal cancer, Colorectal Cancer Treatments and Studies, Lymphoma Diagnosis and Treatment, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial(2009)1,152 cited
- → Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features(2014)663 cited
- → Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer(2012)276 cited
- → Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial(2014)235 cited
- → Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis(2015)211 cited
- → Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)(2015)183 cited
- → Concurrent chemoradiotherapy vs . radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis(2017)152 cited
- → Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)(2013)129 cited
- → The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-randomized phase III study (SAKK 95/06)(2015)128 cited
- → Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations(2020)112 cited